Treatment with bisphosphonates in severe hypercalcemia due to subcutaneous fat necrosis in an infant with hypoxic-ischemic encephalopathy

Martínez, Eric; Camprubí, Marta Camprubí; Cebrián, Mireia; López, Jordi Antón; Saracho, Asier Apodaca; Ramos, María Goretti López; García‐Alix, Alfredo

doi:10.1038/jp.2014.28

Cited by 13 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The exact duration of monitoring for hypercalcaemia remains unclear. Hypercalcaemia is managed by hydration, dietary restriction of calcium and vitamin D, calcium-wasting diuretics (e.g., furosemide), calcitonin, bisphosphonates (e.g., etidronate) [8] and systemic corticosteroids.…”

Section: Discussion/conclusionmentioning

confidence: 99%

Report of 2 Novel Presentations of Subcutaneous Fat Necrosis of the Newborn

Kannenberg¹,

Jordaan²,

Visser³

et al. 2019

Dermatopathology

View full text Add to dashboard Cite

Subcutaneous fat necrosis of the newborn (SCFNN) is a rare form of panniculitis classically affecting healthy full-term infants. There are a number of predisposing factors including perinatal asphyxia. The condition generally has a benign course with spontaneous resolution, but monitoring for metabolic complications, in particular the potentially life-threatening complication of hypercalcaemia, is critical. The authors report 2 cases of preterm infants with perinatal asphyxia with atypical presentations of SCFNN: the first with bony involvement resembling Langerhans cell histiocytosis and with follicular pseudocarcinomatous hyperplasia on histology; and the second presenting with a huge haematoma requiring surgical debridement. Both cases were initially erroneously diagnosed as pyogenic infections.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Report of 2 Novel Presentations of Subcutaneous Fat Necrosis of the Newborn

Kannenberg¹,

Jordaan²,

Visser³

et al. 2019

Dermatopathology

View full text Add to dashboard Cite

show abstract

“…10 Pérez Martínez et al provided further evidence of etidronate as an alternative and effective treatment for moderate-tosevere hypercalcemia. 11 Trullemans et al reported the case of a patient presenting with symptomatic hypercalcemia complicated by nephrocalcinosis consecutive to SCFN after birth asphyxia at term. Oral etidronate was then used for 3 weeks after failure of standard treatment, and the evolution was favorable.…”

Section: Discussionmentioning

confidence: 99%

Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia

Militello

Re²,

Vitaliti

et al. 2019

Amer J Perinatol

View full text Add to dashboard Cite

Objective Subcutaneous fat necrosis (SCFN) is a rare condition that may occur in the neonatal period. SCFN is an inflammatory disorder of the adipose tissue, usually found in full-term healthy infants who have a history of intrauterine or perinatal distress. It is usually a self-limited condition; however, in some cases, it can get complicated, leading to severe hypercalcemia that may be life-threatening. Study Design We report and describe a classic presentation of SCFN that led to severe hypercalcemia refractory to standard treatment. The diagnosis of SCFN was made based on the finding of subcutaneous nodules and of hypercalcemia. The serum calcium level reached 16.6 mg/dL. Hypercalcemia was treated first with intravenous infusions of fluids and furosemide and then of methylprednisolone. This standard treatment was not effective; therefore, we administered a single low dose of zoledronic acid, which, in turn, was efficacious in ultimately managing the hypercalcemia. Conclusion Our case shows how a single low dose of zoledronic acid was safe and effective in managing severe hypercalcemia unresponsive to conventional treatment while minimizing the risk of hypocalcemic rebounds.

show abstract

“…Treatment of hypercalcemia consists of hyperhydration and diet with low levels of calcium and vitamin D; sometimes, other drugs like furosemide and prednisolone are needed to decrease serum calcium 2; bisphosphonates (e.g., etidronate) may also be employed to treat moderate to severe hypercalcemia when other measures have proven ineffective 10.…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous fat necrosis of the newborn

Rubin

Spagnut

Morandi

et al. 2015

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageSubcutaneous fat necrosis (SCFN) is a rare fat tissue inflammation of the newborn. Risk factors include cord prolapse, perinatal asphyxia, therapeutic hypothermia, meconium aspiration, and sepsis. When present, hypercalcemia comes with lethargy, hypotonia, irritability, vomiting, polyuria, polydipsia, constipation, and dehydration. Kidney injury must be avoided. SCFN is often completely autoresolutive.

show abstract

Treatment with bisphosphonates in severe hypercalcemia due to subcutaneous fat necrosis in an infant with hypoxic-ischemic encephalopathy

Cited by 13 publications

References 3 publications

Report of 2 Novel Presentations of Subcutaneous Fat Necrosis of the Newborn

Report of 2 Novel Presentations of Subcutaneous Fat Necrosis of the Newborn

Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia

Subcutaneous fat necrosis of the newborn

Contact Info

Product

Resources

About